"s of the vertebrae and/or ribs were observed in conjunction with decreased maternal food intake and decreased weight gain attributed to the pharmacology of dulaglutide at 0.41 mg/kg.</p><p>In a prenatal-postnatal study in F<span class=\\\"Sub\\\">0</span> maternal rats given subcutaneous doses of 0.2, 0.49, or 1.63 mg/kg every third day from implantation through lactation, systemic exposures in pregnant rats were 1-, 2-, and 7-times human exposure at the MRHD, based on plasma AUC comparison. F<span class=\\\"Sub\\\">1</span> pups from F<span class=\\\"Sub\\\">0</span> maternal rats given 1.63 mg/kg dulaglutide had statistically significantly lower mean body weight from birth through postnatal day 63 for males and postnatal day 84 for females. F<span class=\\\"Sub\\\">1</span> offspring from F<span class=\\\"Sub\\\">0</span> maternal rats receiving 1.63 mg/kg dulaglutide had decreased forelimb and hindlimb grip strength and males had delayed balano-preputial separation. Females had decreased startle response. These physical findings may relate to the decreased size of the offspring relative to controls as they appeared at early postnatal assessments but were not observed at a later assessment. F<span class=\\\"Sub\\\">1</span> female offspring of the F<span class=\\\"Sub\\\">0</span> maternal rats given 1.63 mg/kg of dulaglutide had a longer mean escape time and a higher mean number of errors relative to concurrent control during 1 of 2 trials in the memory evaluation portion of the Biel water maze. These findings occurred in conjunction with decreased F<span class=\\\"Sub\\\">0</span> maternal food intake and decreased weight gain attributed to the pharmacologic activity at 1.63 mg/kg. The human relevance of these memory deficits in the F<span class=\\\"Sub\\\">1</span> female rats is not known.</p></div></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"77290-5\\\"><a name=\\\"s47\\\"></a><a name=\\\"section-8.2\\\"></a><p></p><h2>8.2 Lactation</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s48\\\"></a><a name=\\\"section-8.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Risk Summary</span></p><p>There are no data on the presence of dulaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. The presence of dulaglutide in milk of treated lactating animals was not determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TRULICITY and any potential adverse effects on the breastfed infant from TRULICITY or from the underlying maternal condition.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"34081-0\\\"><a name=\\\"s49\\\"></a><a name=\\\"section-8.3\\\"></a><p></p><h2>8.4 Pediatric Use</h2><p class=\\\"First\\\">The safety and effectiveness of TRULICITY as an adjunct to diet and exercise to improve glycemic control in pediatric patients 10 years of age and older with type 2 diabetes mellitus have been established. Use of TRULICITY for this indication is supported by a 26-week, multicenter, randomized, double-blind, parallel arm, placebo-controlled trial in 154 pediatric patients 10 years of age and older with type 2 diabetes mellitus <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s90\\\">14.6</a>)]</span>.</p><p>TRULICITY-treated pediatric patients reported a higher incidence of injection site-related reactions compared to TRULICITY-treated adults <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s22\\\">6.1</a>)]</span>.</p><p>The safety and effectiveness of TRULICITY have not been established in pediatric patients less than 10 years of age.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"34082-8\\\"><a name=\\\"s50\\\"></a><a name=\\\"section-8.4\\\"></a><p></p><h2>8.5 Geriatric Use</h2><p class=\\\"First\\\">In the adult glycemic control trials <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s78\\\">14.2</a>, <a href=\\\"#s79\\\">14.3</a>)]</span>, 620 (19%) of TRULICITY-treated patients were 65 years of age or older and 65 (2%) of TRULICITY-treated patients were 75 years of age or older at baseline. In the TRULICITY 1.5 mg treatment arm of the REWIND trial (cardiovascular outcomes trial in adults with type 2 diabetes mellitus and cardiovascular disease or multiple cardiovascular risk factors) <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s89\\\">14.5</a>)]</span>, 2,619 (53%) patients were 65 years of age or older, and 484 (10%) patients were 75 years of age or older at baseline.</p><p>No overall differences in safety or effectiveness for TRULICITY have been observed between patients 65 years of age and older and younger adult patients.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"88828-9\\\"><a name=\\\"s51\\\"></a><a name=\\\"section-8.5\\\"></a><p></p><h2>8.6 Renal Impairment</h2><p class=\\\"First\\\">TRULICITY has been studied in patients with varying degrees of renal function, including a dedicated clinical trial in patients with moderate to severe chronic kidney disease. No overall differences in safety or effectiveness were observed in these studies according to renal function <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s78\\\">14.2</a>, <a href=\\\"#s79\\\">14.3</a>, <a href=\\\"#s88\\\">14.4</a>)]</span>.</p><p>In a clinical pharmacology study in patients with renal impairment, including end-stage renal disease (ESRD), no clinically relevant change in dulaglutide pharmacokinetics (PK) was observed. In the 52-week trial in patients with type 2 diabetes and moderate to severe renal impairment, the PK behavior of TRULICITY 0.75 mg and 1.5 mg once weekly was similar to that demonstrated in previous clinical studies <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s64\\\">12.3</a>)]</span>.</p><p>No dose adjustment is recommended in patients with renal impairment including end-stage renal disease (ESRD). Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions. Use TRULICITY with caution in patients with ESRD <span class=\\\"Italics\\\">[see Warning and Precautions (<a href=\\\"#s16\\\">5.5</a>), Clinical Pharmacology (<a href=\\\"#s64\\\">12.3</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"88829-7\\\"><a name=\\\"s52\\\"></a><a name=\\\"section-8.6\\\"></a><p></p><h2>8.7 Hepatic Impairment</h2><p class=\\\"First\\\">In a clinical pharmacology study in patients with varying degrees of hepatic impairment, no clinically relevant change in dulaglutide PK was observed <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s64\\\">12.3</a>)]</span>. However, there is limited clinical experience in patients with mild, moderate, or severe hepatic impairment; therefore, use TRULICITY with caution in these patient populations.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s53\\\"></a><a name=\\\"section-8.7\\\"></a><p></p><h2>8.8 Gastroparesis</h2><p class=\\\"First\\\">Dulaglutide slows gastric emptying. TRULICITY has not been studied in patients with preexisting gastroparesis. Use TRULICITY with caution in patients with gastroparesis.</p></div></section>\",\n            \"description\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34089-3\\\"><a name=\\\"s55\\\"></a><a name=\\\"section-10\\\"></a><p></p><h1>11 DESCRIPTION</h1><p class=\\\"First\\\">Dulaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell (Chinese hamster ovary) culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37). Structural modifications were introduced in the GLP-1 part of the molecule responsible for interaction with the enzyme dipeptidyl-peptidase-IV (DPP-4). Additional modifications were made in an area with a potential T-cell epitope and in the areas of the IgG4 Fc part of the molecule responsible for binding the high-affinity Fc receptors and half-antibody formation. The overall molecular weight of dulaglutide is approximately 63 kilodaltons.</p><p>TRULICITY (dulaglutide) injection is a clear, colorless, sterile, preservative-free solution for subcutaneous use. Each single-dose pen contains a 0.5 mL solution of 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg of dulaglutide and the following excipients: citric acid anhydrous (0.07 mg), mannitol (23.2 mg), polysorbate 80 (0.10 mg for 0.75 mg and 1.5 mg; 0.125 mg for 3 mg and 4.5 mg), and trisodium citrate dihydrate (1.37 mg), in water for injection.</p></section>\",\n            \"nonclinicalToxicology\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43680-8\\\"><a name=\\\"s73\\\"></a><a name=\\\"section-12\\\"></a><p></p><h1>13 NONCLINICAL TOXICOLOGY</h1><div class=\\\"Section\\\" data-sectioncode=\\\"34083-6\\\"><a name=\\\"s74\\\"></a><a name=\\\"section-12.1\\\"></a><p></p><h2>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2><p class=\\\"First\\\">A 2-year carcinogenicity study was conducted with dulaglutide in male and female rats at doses of 0.05, 0.5, 1.5, and 5 mg/kg (0.2-, 3-, 8-, and 24-fold the MRHD of 4.5 mg once weekly based on AUC) administered by subcutaneous injection twice weekly. In rats, dulaglutide caused a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and/or carcinomas) compared to controls, at ≥3-fold the MRHD based on AUC. A statistically significant increase in C-cell adenomas was observed in rats receiving dulaglutide at ≥0.5 mg/kg. Numerical increases in thyroid C-cell carcinomas occurred at 5 mg/kg (24 times the MRHD based on AUC) and were considered to be treatment-related despite the absence of statistical significance.</p><p>A 6-month carcinogenicity study was conducted with dulaglutide in rasH2 transgenic mice at doses of 0.3, 1, and 3 mg/kg administered by subcutaneous injection twice weekly. Dulaglutide did not produce increased incidences of thyroid C-cell hyperplasia or neoplasia at any dose.</p><p>Dulaglutide is a recombinant protein; no genotoxicity studies have been conducted.</p><p>Human relevance of thyroid C-cell tumors in rats is unknown and could not be determined by clinical studies or nonclinical studies <span class=\\\"Italics\\\">[see <a href=\\\"#s2\\\">Boxed Warning</a> and Warnings and Precautions (<a href=\\\"#s12\\\">5.1</a>)]</span>.</p><p>In fertility and early embryonic development studies in male and female rats, no adverse effects of dulaglutide on sperm morphology, mating, fertility, conception, and embryonic survival were observed at up to 16.3 mg/kg (55-fold the MRHD based on AUC). In female rats, an increase in the number of females with prolonged diestrus and a dose-related decrease in the mean number of corpora lutea, implantation sites, and viable embryos were observed at ≥4.9 mg/kg (≥13-fold the MRHD based on AUC), which occurred in the presence of decreased maternal food consumption and body weight gain.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"34091-9\\\"><a name=\\\"s75\\\"></a><a name=\\\"section-12.2\\\"></a><p></p><h2>13.2 Animal Toxicology and/or Pharmacology</h2><p class=\\\"First\\\">Zucker diabetic fatty (ZDF) rats were given 0.5, 1.5, or 5 mg/kg/twice weekly of dulaglutide (1-, 3-, and 13-fold the MRHD based on AUC) for 3 months. Increases of 12% to 33% in total and pancreatic amylase, but not lipase, were observed at all doses without microscopic pancreatic inflammatory correlates in individual animals. Other changes in the dulaglutide-treated animals included increased interlobular ductal epithelium without active ductal cell proliferation (≥0.5 mg/kg), increased acinar atrophy with/without inflammation (≥1.5 mg/kg), and increased neutrophilic inflammation of the acinar pancreas (5 mg/kg).</p><p>Treatment of monkeys for 12 months with 8.15 mg/kg/twice weekly of dulaglutide (nearly 200-fold the MRHD based on AUC) demonstrated no evidence of pancreatic inflammation or pancreatic intraepithelial neoplasia. In 4 of 19 monkeys on dulaglutide treatment, there was an increase in goblet cells within the pancreatic ducts, but no differences from the control group in total amylase or lipase at study termination. There were no proliferative changes in the thyroid C-cells.</p></div></section>\",\n            \"instructionsForUse\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"59845-8\\\"><a name=\\\"s99\\\"></a><a name=\\\"section-20\\\"></a><p></p><h1>TRULICITY 4.5 MG SINGLE-DOSE PEN INSTRUCTIONS FOR USE</h1><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"13.200%\\\"/><col align=\\\"left\\\" width=\\\"73.300%\\\"/><col align=\\\"left\\\" width=\\\"13.500%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"center\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Instructions for Use</span></td><td align=\\\"center\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"center\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">TRULICITY</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">®</span></span><span class=\\\"Bold\\\">(TRU-li-si-tee)</span><br/><span class=\\\"Bold\\\">(dulaglutide)</span><br/><span class=\\\"Bold\\\">injection, for subcutaneous use</span><br/><span class=\\\"Bold\\\">4.5 mg/0.5 mL Single-Dose Pen</span><br/><span class=\\\"Bold\\\">use 1 time each week (once weekly)</span><br/><br/><a name=\\\"f20-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-sup-4point5-pen-v1.jpg\\\"/><br/><br/><a name=\\\"f21-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-unfold-v1.jpg\\\"/></td><td align=\\\"center\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"right\\\" class=\\\"Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" class=\\\"Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" class=\\\"Toprule\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><a name=\\\"f21a-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Logo\\n\\\" src=\\\"logo.jpg\\\"/></p></td></tr></tbody></table><p class=\\\"First\\\"><span class=\\\"Bold\\\">Information About TRULICITY Single-Dose Pen</span></p><p><span class=\\\"Bold\\\">Please read this Instructions for Use and the Medication Guide carefully and completely before using your TRULICITY Single-Dose Pen. Talk to your healthcare provider about how to inject TRULICITY the right way.</span></p><ul class=\\\"Disc\\\"><li>TRULICITY Single-Dose Pen (Pen) is a disposable, prefilled medicine delivery device. Each Pen contains 1 dose of TRULICITY (4.5 mg/0.5 mL). Each Pen should only be used 1 time.</li><li><span class=\\\"Bold\\\">TRULICITY is used 1 time each week.</span> You may want to mark your calendar to remind you when to take your next dose.</li></ul><p><span class=\\\"Bold\\\">Before You Get Started</span></p><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"25.000%\\\"/><col align=\\\"left\\\" width=\\\"25.000%\\\"/><col align=\\\"left\\\" width=\\\"25.000%\\\"/><col align=\\\"left\\\" width=\\\"25.000%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><a name=\\\"f22-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-remove-v1.jpg\\\"/></p></td><td align=\\\"left\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><a name=\\\"f23-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-check-v1.jpg\\\"/></p></td><td align=\\\"left\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><a name=\\\"f24-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-inspect-v1.jpg\\\"/></p></td><td align=\\\"left\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><a name=\\\"f25-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-prepare-v1.jpg\\\"/></p></td></tr><tr><td align=\\\"left\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Remove</span></td><td align=\\\"left\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Check</span></td><td align=\\\"left\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Inspect</span></td><td align=\\\"left\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Prepare</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\">Remove the Pen from the refrigerator.<br/>Leave the Base Cap on until you are ready to inject.</td><td align=\\\"left\\\" valign=\\\"top\\\">Check the Pen label to make sure you have the right medicine and it has not expired.<br/>Expiration Date         <br/><br/><a name=\\\"f26-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-expiration-location-v2.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"top\\\">Check the Pen to make sure that it is not damaged and inspect the medicine to make sure it is not cloudy, discolored or has particles in it.</td><td align=\\\"left\\\" valign=\\\"top\\\">Wash your hands.</td></tr></tbody></table><p><span class=\\\"Bold\\\">Choose Your Injection Site</span></p><p>Your healthcare provider can help you choose the injection site that is best for you.</p><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"25.000%\\\"/><col align=\\\"left\\\" width=\\\"75.000%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" valign=\\\"top\\\"><a name=\\\"f27a-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-4point5mg-injection-sites-front-v1.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"top\\\">Change (rotate) your injection site each week. You may use the same area of your body, but be sure to choose a different injection site in that area.<br/><br/>You may inject the medicine into your stomach (abdomen) or thigh.</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><a name=\\\"f27b-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-4point5mg-injection-sites-back-v1.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"top\\\"><br/><br/>Another person should give you the injection in the back of your upper arm.</td></tr></tbody></table><p><a name=\\\"f28-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-sup-4point5-pen-parts-v1.jpg\\\"/></p><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"40.633%\\\"/><col align=\\\"left\\\" width=\\\"1.967%\\\"/><col align=\\\"left\\\" width=\\\"57.400%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><span class=\\\"Bold\\\">Step 1 Uncap the Pen</span><br/><a name=\\\"f28a-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Locked\\n\\\" src=\\\"trulicity-ifu-locked-v1.jpg\\\"/> Make sure the Pen is <span class=\\\"Bold\\\">locked</span>.<br/></p><ul class=\\\"Disc\\\"><li>Pull the Base Cap straight off and throw it away in your household trash.<br/><span class=\\\"Bold\\\">Do not put the Base Cap back on — this could damage the needle.<br/>Do not touch the needle.</span></li></ul></td><td align=\\\"center\\\" valign=\\\"top\\\"><br/><a name=\\\"f29-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-sup-4point5-f2-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 2 Place and Unlock</span><br/><ul class=\\\"Disc\\\"><li><p class=\\\"First\\\">Place the Clear Base flat and firmly against your skin at the injection site            .<br/></p></li></ul><p class=\\\"First\\\"><a name=\\\"f29a-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Unlocked\\n\\\" src=\\\"trulicity-ifu-unlock-v1.jpg\\\"/><span class=\\\"Bold\\\">Unlock</span> by turning the Lock Ring.</p></td><td align=\\\"center\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><br/><a name=\\\"f30-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-sup-4point5-f3-v1.jpg\\\"/></td></tr></tbody></table><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"40.600%\\\"/><col align=\\\"left\\\" width=\\\"1.950%\\\"/><col align=\\\"left\\\" width=\\\"57.350%\\\"/><col align=\\\"left\\\" width=\\\"10%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Step 3 Press and Hold</span><br/><ul class=\\\"Disc\\\"><li><p class=\\\"First\\\">Press and hold the green Injection Button. You will hear a loud click.            <br/><a name=\\\"f30a-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Exclamation\\n\\\" src=\\\"trulicity-ifu-exclamation-v1.jpg\\\"/>Continue holding the Clear Base firmly against your skin until you hear a second click. This happens when the needle starts retracting in about 5-10 seconds.</p></li><li>Remove the Pen from your skin.</li></ul></td><td align=\\\"center\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><a name=\\\"f31-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-sup-4point5-f4-v1.jpg\\\"/></td></tr></tbody></table><p><span class=\\\"Bold\\\">Important Information</span></p><p>Disposal of Pen</p><p>Storage and Handling</p><p>Commonly Asked Questions</p><p>Other Information</p><p>Where to Learn More</p><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"57.500%\\\"/><col align=\\\"left\\\" width=\\\"42.500%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Disposing of Your Used Pens</span><br/><ul class=\\\"Disc\\\"><li>Put your used Pens in a FDA-cleared sharps disposal container right away after use. <span class=\\\"Bold\\\">Do not throw away (dispose of) Pens in your household trash.</span></li><li>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:<dl class=\\\"Disc\\\"><dt>-</dt><dd>made of a heavy-duty plastic,</dd><dt>-</dt><dd>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</dd><dt>-</dt><dd>upright and stable during use,</dd><dt>-</dt><dd>leak-resistant, and</dd><dt>-</dt><dd>properly labeled to warn of hazardous waste inside the container.</dd></dl></li><li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.</li><li><span class=\\\"Bold\\\">Do not</span> recycle your used sharps disposal container.</li></ul></td><td align=\\\"center\\\" valign=\\\"top\\\"><br/><a name=\\\"f32-ifu-sup-4point5-pen\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"trulicity-ifu-sup-4point5-f5-v1.jpg\\\"/></td></tr></tbody></table><p><span class=\\\"Bold\\\">Storage and Handling</span></p><ul class=\\\"Disc\\\"><li>Store your Pen in the refrigerator between 36°F to 46°F (2°C to 8°C).</li><li>You may store your Pen at room temperature below 86°F (30°C) for a total of 14 days.</li><li>Do not freeze your Pen. If the Pen has been frozen, throw the Pen away and use a new Pen.</li><li>Storage of your Pen in the original carton is recommended. Protect your Pen from direct heat and light.</li><li>The Pen has glass parts. Handle it carefully. If you drop it on a hard surface, do not use it. Use a new Pen for your injection.</li><li>Keep your TRULICITY Pen and all medicines out of the reach of children.</li></ul><p><span class=\\\"Bold\\\">Commonly Asked Questions</span></p><p><span class=\\\"Bold\\\">What if I see air bubbles in my Pen?</span></p><p>Air bubbles are normal.</p><p><span class=\\\"Bold\\\">What if I unlock the Pen and press the green Injection Button before pulling off the Base Cap?</span></p><p>Do not remove the Base Cap. Throw away the Pen and get a new Pen.</p><p><span class=\\\"Bold\\\">What if there is a drop of liquid on the tip of the needle when I remove the Base Cap?</span></p><p>A drop of liquid on the tip of the needle is normal.</p><p><span class=\\\"Bold\\\">Do I need to hold the Injection Button down until the injection is complete?</span></p><p>This is not necessary, but it may help you keep the Pen steady and firm against your skin.</p><p><span class=\\\"Bold\\\">I heard more than 2 clicks during my injection—2 louder clicks and 1 soft one. Did I get my complete injection?</span></p><p>Some people may hear a soft click right before the second loud click. That is the normal operation of the Pen. Do not remove the Pen from your skin until you hear the second louder click.</p><p><span class=\\\"Bold\\\">What if there is a drop of liquid or blood on my skin after my injection?</span></p><p>This is normal.</p><p><span class=\\\"Bold\\\">I am not sure if my Pen worked the right way.</span></p><p>Check to see if you have received your dose. Your dose was delivered the right way if the gray plunger is visible <span class=\\\"Italics\\\">(see step 3)</span>. Also contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) for further instructions. Until then, store your Pen safely to avoid an accidental needle stick.</p><p><span class=\\\"Bold\\\">Other Information</span></p><ul class=\\\"Disc\\\"><li>If you have vision problems, do not use your Pen without help from a person trained to use the TRULICITY Pen.</li></ul><p><span class=\\\"Bold\\\">Where to Learn More</span></p><ul class=\\\"Disc\\\"><li>If you have any questions or problems with your TRULICITY Single-Dose Pen, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider.</li><li>For more information about TRULICITY Single-Dose Pen, visit our website at: www.trulicity.com.</li></ul><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"14.167%\\\"/><col align=\\\"left\\\" width=\\\"36.667%\\\"/><col align=\\\"left\\\" width=\\\"49.167%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" valign=\\\"top\\\"><br/><a name=\\\"f32a-ifu-sup-4point5-pen\\\"></a><img alt=\\\"QR Code\\n\\\" src=\\\"qr-v1.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Scan this code to launch <br/>www.trulicity.com</span></td><td align=\\\"left\\\" valign=\\\"top\\\"></td></tr></tbody></table><p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.<br/>Eli Lilly and Company<br/>Indianapolis, IN 46285, USA      <br/>US License Number 1891<br/>TRULICITY is a registered trademark of Eli Lilly and Company.</p><p>Copyright © 2020, 2023, Eli Lilly and Company. All rights reserved.</p><p>The TRULICITY Pen meets the current dose accuracy and functional requirements of ISO 11608-1:2012 and 11608-5:2012.</p><p>Implemented: 04/2023</p><p>TRU4.5MG-0002-IFU-20230407</p></section>\",\n            \"mechanismOfAction\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43679-0\\\"><a name=\\\"s57\\\"></a><a name=\\\"section-11.1\\\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\\\"First\\\">TRULICITY contains dulaglutide, which is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.</p></section>\",\n            \"contraindications\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34070-3\\\"><a name=\\\"s10\\\"></a><a name=\\\"section-4\\\"></a><p></p><h1>4 CONTRAINDICATIONS</h1><p class=\\\"First\\\">TRULICITY is contraindicated in patients with:</p><ul class=\\\"Disc\\\"><li>Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s12\\\">5.1</a>)]</span>.</li><li>Serious hypersensitivity reaction to dulaglutide or to any of the product components. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with TRULICITY <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s15\\\">5.4</a>)]</span>.</li></ul></section>\",\n            \"highlights\": {\n                \"dosageAndAdministration\": \"<div><p class=\\\"Highlighta\\\"><span class=\\\"Underline\\\">Adult Dosage (<a href=\\\"#s5\\\">2.1</a>)</span> </p><ul class=\\\"Disc\\\"><li>Recommended starting dosage is 0.75 mg injected subcutaneously once weekly.</li><li>After 4 weeks, the dosage may be increased to 1.5 mg once weekly for additional glycemic control.</li><li>If additional glycemic control is needed, increase dosage in 1.5 mg increments after at least 4 weeks on the current dosage.</li><li>Maximum recommended dosage is 4.5 mg injected subcutaneously once weekly.</li></ul><p class=\\\"Highlighta\\\"><span class=\\\"Underline\\\">Pediatric Dosage (<a href=\\\"#s6\\\">2.2</a>)</span> </p><ul class=\\\"Disc\\\"><li>Recommended starting dosage is 0.75 mg injected subcutaneously once weekly.</li><li>If additional glycemic control is needed, increase dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage.</li></ul><p class=\\\"Highlighta\\\"><span class=\\\"Underline\\\">Recommendations Regarding Missed Dose (<a href=\\\"#s7\\\">2.3</a>)</span> </p><ul class=\\\"Disc\\\"><li>If a dose is missed, administer the missed dose as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose.</li></ul><p class=\\\"Highlighta\\\"><span class=\\\"Underline\\\">Important Administration Instructions (<a href=\\\"#s8\\\">2.4</a>)</span> </p><ul class=\\\"Disc\\\"><li>Administer once weekly at any time of day with or without food.</li><li>Inject subcutaneously in the abdomen, thigh, or upper arm.</li></ul></div>\"\n            }\n        }\n    },\n    {\n        \"drugName\": \"Verzenio\",\n        \"setId\": \"be4bc0de-0fdc-4d46-8d25-be43c79e6a06\",\n        \"slug\": \"verzenio-be4bc0d\",\n        \"labeler\": \"Eli Lilly and Company\",\n        \"label\": {\n            \"genericName\": \"abemaciclib\",\n            \"labelerName\": \"Eli Lilly and Company\",\n            \"productType\": \"HUMAN PRESCRIPTION DRUG LABEL\",\n            \"effectiveTime\": \"20241113\",\n            \"title\": \"Verzenio\",\n            \"indicationsAndUsage\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34067-9\\\"><a name=\\\"s2\\\"></a><a name=\\\"section-1\\\"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s3\\\"></a><a name=\\\"section-1.1\\\"></a><p></p><h2>1.1 Early Breast Cancer</h2><p class=\\\"First\\\">VERZENIO<span class=\\\"Sup\\\">®</span> (abemaciclib) is indicated:</p><ul class=\\\"Disc\\\"><li>          in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s98\\\">14.1</a>)].</span></li></ul></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s4\\\"></a><a name=\\\"section-1.2\\\"></a><p></p><h2>1.2 Advanced or Metastatic Breast Cancer</h2><p class=\\\"First\\\">         VERZENIO (abemaciclib) is indicated:</p><ul class=\\\"Disc\\\"><li>          in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.</li><li>          in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.</li><li>as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.</li></ul></div></section>\",\n            \"dosageAndAdministration\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34068-7\\\"><a name=\\\"s5\\\"></a><a name=\\\"section-2\\\"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s8\\\"></a><a name=\\\"section-2.1\\\"></a><p></p><h2>2.1 Recommended Dose and Schedule</h2><ul class=\\\"Disc\\\"><li>When used in combination with fulvestrant, tamoxifen, or an aromatase inhibitor, the recommended dose of VERZENIO is 150 mg taken orally twice daily. Refer to the Full Prescribing Information for the recommended dose of the fulvestrant, tamoxifen, or aromatase inhibitor being used.</li><li>Pre/perimenopausal women and men treated with the combination of VERZENIO plus an aromatase inhibitor should be treated with a gonadotropin-releasing hormone agonist (GnRH) according to current clinical practice standards.</li><li>Pre/perimenopausal women treated with the combination of VERZENIO plus fulvestrant should be treated with a GnRH according to current clinical practice standards</li><li>When used as monotherapy, the recommended dose of VERZENIO is 200 mg taken orally twice daily.</li><li>          For early breast cancer, continue VERZENIO until completion of 2 years of treatment or until disease recurrence, or unacceptable toxicity.</li><li>For advanced or metastatic breast cancer, continue treatment until disease progression or unacceptable toxicity.</li></ul><p class=\\\"First\\\">VERZENIO may be taken with or without food <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s67\\\">12.3</a>)]</span>.</p><p>Instruct patients to take their doses of VERZENIO at approximately the same times every day.</p><p>If the patient vomits or misses a dose of VERZENIO, instruct the patient to take the next dose at its scheduled time. Instruct patients to swallow VERZENIO tablets whole and not to chew, crush, or split tablets before swallowing. Instruct patients not to ingest VERZENIO tablets if broken, cracked, or otherwise not intact.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s9\\\"></a><a name=\\\"section-2.2\\\"></a><p></p><h2>2.2 Dose Modification</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s10\\\"></a><a name=\\\"section-2.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Dose Modifications for Adverse Reactions</span></p><p>The recommended VERZENIO dose modifications for adverse reactions are provided in <a href=\\\"#t1\\\">Tables 1</a>-<a href=\\\"#t7\\\">7</a>. Discontinue VERZENIO for patients unable to tolerate 50 mg twice daily.</p><a name=\\\"t1\\\"></a><table width=\\\"100%\\\"><caption><span>Table 1: VERZENIO Dose Modification — Adverse Reactions</span></caption><col align=\\\"left\\\" width=\\\"33.333%\\\"/><col align=\\\"left\\\" width=\\\"33.333%\\\"/><col align=\\\"left\\\" width=\\\"33.333%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Dose Level</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO Dose</span><br/><span class=\\\"Bold\\\">Combination with Fulvestrant, Tamoxifen, or an Aromatase Inhibitor</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO Dose</span><br/><span class=\\\"Bold\\\">for Monotherapy</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Recommended starting dose</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">150 mg twice daily</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">200 mg twice daily</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">First dose reduction</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">100 mg twice daily</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">150 mg twice daily</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Second dose reduction</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">50 mg twice daily</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">100 mg twice daily</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Third dose reduction</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">not applicable</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">50 mg twice daily</td></tr></tbody></table><a name=\\\"t2\\\"></a><table width=\\\"100%\\\"><caption><span>Table 2: VERZENIO Dose Modification and Management — Hematologic Toxicities<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"28.300%\\\"/><col align=\\\"left\\\" width=\\\"71.700%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviation: CTCAE = Common Terminology Criteria for Adverse Events.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> If blood cell growth factors are required, suspend VERZENIO dose for at least 48 hours after the last dose of blood cell growth factor and until toxicity resolves to ≤Grade 2. Resume at <span class=\\\"Italics\\\">next lower dose</span> unless already performed for the toxicity that led to the use of the growth factor. Growth factor use as per current treatment guidelines.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\">Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">CTCAE Grade</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO Dose Modifications</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 1 or 2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">No dose modification is required.</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Suspend dose until toxicity resolves to ≤Grade 2.<br/>Dose reduction is not required.</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 3 recurrent, or Grade 4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Suspend dose until toxicity resolves to ≤Grade 2.<br/>Resume at <span class=\\\"Italics\\\">next lower dose</span>.</td></tr></tbody></table><a name=\\\"t3\\\"></a><table width=\\\"100%\\\"><caption><span>Table 3: VERZENIO Dose Modification and Management — Diarrhea</span></caption><col align=\\\"left\\\" width=\\\"51.200%\\\"/><col align=\\\"left\\\" width=\\\"48.800%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\">At the first sign of loose stools, start treatment with antidiarrheal agents and increase intake of oral fluids.</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">CTCAE Grade</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO Dose Modifications</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">No dose modification is required.</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">If toxicity does not resolve within 24 hours to ≤Grade 1, suspend dose until resolution. No dose reduction is required.</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 2 that persists or recurs after resuming the same dose despite maximal supportive measures</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Suspend dose until toxicity resolves to ≤Grade 1.<br/>Resume at <span class=\\\"Italics\\\">next lower dose</span>.</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 3 or 4 or requires hospitalization</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Suspend dose until toxicity resolves to ≤Grade 1.<br/>Resume at <span class=\\\"Italics\\\">next lower dose</span>.</td></tr></tbody></table><a name=\\\"t4\\\"></a><table width=\\\"100%\\\"><caption><span>Table 4: VERZENIO Dose Modification and Management — Hepatotoxicity</span></caption><col align=\\\"left\\\" width=\\\"46.650%\\\"/><col align=\\\"left\\\" width=\\\"53.350%\\\"/><tfoot><tr class=\\\"First Last\\\"><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\">Monitor ALT, AST, and serum bilirubin prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">CTCAE Grade for ALT and AST</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO Dose Modifications</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 1 (&gt;ULN-3.0 x ULN)<br/>Grade 2 (&gt;3.0-5.0 x ULN),<br/>WITHOUT increase in total bilirubin above 2 x ULN</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">No dose modification is required.</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Persistent or Recurrent Grade 2, or Grade 3 (&gt;5.0-20.0 x ULN), WITHOUT increase in total bilirubin above 2 x ULN</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">Suspend dose until toxicity resolves to baseline or Grade 1.<br/>Resume at next lower dose.</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Elevation in AST and/or ALT &gt;3 x ULN WITH total bilirubin &gt;2 x ULN, in the absence of cholestasis</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">Discontinue VERZENIO.</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 4 (&gt;20.0 x ULN)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">Discontinue VERZENIO.</td></tr></tbody></table><a name=\\\"t5\\\"></a><table width=\\\"100%\\\"><caption><span>Table 5: VERZENIO Dose Modification and Management — Interstitial Lung Disease/Pneumonitis</span></caption><col align=\\\"left\\\" width=\\\"51.200%\\\"/><col align=\\\"left\\\" width=\\\"48.800%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">CTCAE Grade</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO Dose Modifications</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 1 or 2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">No dose modification is required.</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Persistent or recurrent Grade 2 toxicity that does not resolve with maximal supportive measures within 7 days to baseline or Grade 1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">Suspend dose until toxicity resolves to baseline or ≤Grade 1.<br/>Resume at <span class=\\\"Italics\\\">next lower dose</span>.</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 3 or 4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">Discontinue VERZENIO.</td></tr></tbody></table><a name=\\\"t6\\\"></a><table width=\\\"100%\\\"><caption><span>Table 6: VERZENIO Dose Modification and Management — Venous Thromboembolic Events (VTEs)</span></caption><col align=\\\"left\\\" width=\\\"50.700%\\\"/><col align=\\\"left\\\" width=\\\"49.300%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">CTCAE Grade</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO Dose Modifications</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Early Breast Cancer</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">              Any Grade</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">Suspend dose and treat as clinically indicated. Resume VERZENIO when the patient is clinically stable.</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Advanced or Metastatic Breast Cancer</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">              Grade 1 or 2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">No dose modification is required.</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">              Grade 3 or 4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Suspend dose and treat as clinically indicated. Resume VERZENIO when the patient is clinically stable.</td></tr></tbody></table><a name=\\\"t7\\\"></a><table width=\\\"100%\\\"><caption><span>Table 7: VERZENIO Dose Modification and Management — Other Toxicities<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"51.200%\\\"/><col align=\\\"left\\\" width=\\\"48.800%\\\"/><tfoot><tr class=\\\"First Last\\\"><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Excluding diarrhea, hematologic toxicity, hepatotoxicity, ILD/pneumonitis, and VTEs.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">CTCAE Grade</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO Dose Modifications</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 1 or 2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">No dose modification is required.</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Persistent or recurrent Grade 2 toxicity that does not resolve with maximal supportive measures within 7 days to baseline or Grade 1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">Suspend dose until toxicity resolves to baseline or ≤Grade 1.<br/>Resume at <span class=\\\"Italics\\\">next lower dose</span>.</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Grade 3 or 4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">Suspend dose until toxicity resolves to baseline or ≤Grade 1.<br/>Resume at <span class=\\\"Italics\\\">next lower dose</span>.</td></tr></tbody></table><p>Refer to the Full Prescribing Information for coadministered fulvestrant, tamoxifen, or an aromatase inhibitor for dose modifications and other relevant safety information.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s11\\\"></a><a name=\\\"section-2.2.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Dose Modification for Use with Strong and Moderate CYP3A Inhibitors</span></p><p>Avoid concomitant use of the strong CYP3A inhibitor ketoconazole.</p><p>With concomitant use of strong CYP3A inhibitors other than ketoconazole, in patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the VERZENIO dose to 100 mg twice daily. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the VERZENIO dose to 50 mg twice daily. If a patient taking VERZENIO discontinues a CYP3A inhibitor, increase the VERZENIO dose (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the strong inhibitor <span class=\\\"Italics\\\">[see Drug Interactions (<a href=\\\"#s39\\\">7.1</a>) and Clinical Pharmacology (<a href=\\\"#s67\\\">12.3</a>)].</span></p><p>With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the VERZENIO dose in 50 mg decrements as demonstrated in <a href=\\\"#t1\\\">Table 1</a>, if necessary.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s12\\\"></a><a name=\\\"section-2.2.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Dose Modification for Patients with Severe Hepatic Impairment</span></p><p>For patients with severe hepatic impairment (Child Pugh-C), reduce the VERZENIO dosing frequency to once daily <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s61\\\">8.7</a>) and Clinical Pharmacology (<a href=\\\"#s67\\\">12.3</a>)].</span></p><p>Refer to the Full Prescribing Information for the coadministered fulvestrant, tamoxifen, or aromatase inhibitor for dose modification requirements for severe hepatic impairment.</p></div></div></section>\",\n            \"dosageFormsAndStrengths\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43678-2\\\"><a name=\\\"s13\\\"></a><a name=\\\"section-3\\\"></a><p></p><h1>3 DOSAGE FORMS AND STRENGTHS</h1><p class=\\\"First\\\">50 mg tablets: oval beige tablet with “Lilly” debossed on one side and “50” on the other side.</p><p>100 mg tablets: oval white to practically white tablet with “Lilly” debossed on one side and “100” on the other side.</p><p>150 mg tablets: oval yellow tablet with “Lilly” debossed on one side and “150” on the other side.</p><p>200 mg tablets: oval beige tablet with “Lilly” debossed on one side and “200” on the other side.</p></section>\",\n            \"warningsAndPrecautions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43685-7\\\"><a name=\\\"s15\\\"></a><a name=\\\"section-5\\\"></a><p></p><h1>5 WARNINGS AND PRECAUTIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s16\\\"></a><a name=\\\"section-5.1\\\"></a><p></p><h2>5.1 Diarrhea</h2><p class=\\\"First\\\">Severe diarrhea associated with dehydration and infection occurred in patients treated with VERZENIO.</p><p>Across four clinical trials in 3691 patients, diarrhea occurred in 81% to 90% of patients who received VERZENIO. Grade 3 diarrhea occurred in 8% to 20% of patients receiving VERZENIO <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s23\\\">6.1</a>)].</span></p><p>Most patients experienced diarrhea during the first month of VERZENIO treatment. The median time to onset of the first diarrhea event ranged from 6 to 8 days; and the median duration of Grade 2 and Grade 3 diarrhea ranged from 6 to 11 days and 5 to 8 days, respectively. Across trials, 19% to 26% of patients with diarrhea required a VERZENIO dose interruption and 13% to 23% required a dose reduction.</p><p>Instruct patients to start antidiarrheal therapy such as loperamide at the first sign of loose stools, increase oral fluids, and notify their healthcare provider for further instructions and appropriate follow up <span class=\\\"Italics\\\">[see Patient Counseling Information (<a href=\\\"#s111\\\">17</a>)].</span> For Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization, discontinue VERZENIO until toxicity resolves to ≤Grade 1, and then resume VERZENIO at the next lower dose <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s9\\\">2.2</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s17\\\"></a><a name=\\\"section-5.2\\\"></a><p></p><h2>5.2 Neutropenia</h2><p class=\\\"First\\\">Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with VERZENIO.</p><p>Across four clinical trials in 3691 patients, neutropenia occurred in a 37% to 46% of patients receiving VERZENIO. A Grade ≥3 decrease in neutrophil count (based on laboratory findings) occurred in 19% to 32% of patients receiving VERZENIO. Across trials, the median time to the first episode of Grade ≥3 neutropenia ranged from 29 days to 33 days, and the median duration of Grade ≥3 neutropenia ranged from 11 days to 16 days <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s23\\\">6.1</a>)]</span>.</p><p>Febrile neutropenia has been reported in &lt;1% of patients exposed to VERZENIO across trials. Two deaths due to neutropenic sepsis were observed in MONARCH 2. Inform patients to promptly report any episodes of fever to their healthcare provider <span class=\\\"Italics\\\">[see Patient Counseling Information (<a href=\\\"#s111\\\">17</a>)]</span>.</p><p>Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s9\\\">2.2</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s18\\\"></a><a name=\\\"section-5.3\\\"></a><p></p><h2>5.3 Interstitial Lung Disease (ILD) or Pneumonitis</h2><p class=\\\"First\\\">Severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis can occur in patients treated with VERZENIO and other CDK4/6 inhibitors. In VERZENIO-treated patients in early breast cancer (monarchE, N=2791), 3% of patients experienced ILD or pneumonitis of any grade: 0.4% were Grade 3 or 4 and there was one fatality (0.1%). In VERZENIO-treated patients in advanced or metastatic breast cancer (N=900) (MONARCH 1, MONARCH 2, MONARCH 3), 3.3% of VERZENIO-treated patients had ILD or pneumonitis of any grade: 0.6% had Grade 3 or 4, and 0.4% had fatal outcomes. Additional cases of ILD or pneumonitis have been observed in the postmarketing setting, with fatalities reported <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s37\\\">6.2</a>)]</span>.</p><p>Monitor patients for pulmonary symptoms indicative of ILD or pneumonitis. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations.</p><p>Dose interruption or dose reduction is recommended for patients who develop persistent or recurrent Grade 2 ILD or pneumonitis. Permanently discontinue VERZENIO in all patients with Grade 3 or 4 ILD or pneumonitis <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s9\\\">2.2</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s19\\\"></a><a name=\\\"section-5.4\\\"></a><p></p><h2>5.4 Hepatotoxicity</h2><p class=\\\"First\\\">Grade ≥3 ALT (2% to 6%) and AST (2% to 3%) were reported in patients receiving VERZENIO.</p><p>Across three clinical trials in 3559 patients (monarchE, MONARCH 2, MONARCH 3), the median time to onset of Grade ≥3 ALT increases ranged from 57 to 87 days and the median time to resolution to Grade &lt;3 was 13 to 14 days. The median time to onset of Grade ≥3 AST increases ranged from 71 to 185 days and the median time to resolution to Grade &lt;3 ranged from 11 to 15 days.</p><p>Monitor liver function tests (LFTs) prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or any Grade 3 or Grade 4 hepatic transaminase elevation <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s9\\\">2.2</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s20\\\"></a><a name=\\\"section-5.5\\\"></a><p></p><h2>        5.5 Venous Thromboembolism</h2><p class=\\\"First\\\">         Across three clinical trials in 3559 patients (monarchE, MONARCH 2, MONARCH 3), venous thromboembolic events were reported in 2% to 5% of patients treated with VERZENIO. Venous thromboembolic events included deep vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, and inferior vena cava thrombosis. In clinical trials, deaths due to venous thromboembolism have been reported in patients treated with VERZENIO.</p><p>         VERZENIO has not been studied in patients with early breast cancer who had a history of venous thromboembolism. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate. Dose interruption is recommended for early breast cancer patients with any grade venous thromboembolic event and for advanced or metastatic breast cancer patients with a Grade 3 or 4 venous thromboembolic event <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s9\\\">2.2</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s21\\\"></a><a name=\\\"section-5.6\\\"></a><p></p><h2>5.6 Embryo-Fetal Toxicity</h2><p class=\\\"First\\\">Based on findings from animal studies and the mechanism of action, VERZENIO can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of abemaciclib to pregnant rats during the period of organogenesis caused teratogenicity and decreased fetal weight at maternal exposures that were similar to the human clinical exposure based on area under the curve (AUC) at the maximum recommended human dose.</p><p>Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with VERZENIO and for 3 weeks after the last dose <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s46\\\">8.1</a>, <a href=\\\"#s52\\\">8.3</a>) and Clinical Pharmacology (<a href=\\\"#s64\\\">12.1</a>)]</span>.</p></div></section>\",\n            \"adverseReactions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34084-4\\\"><a name=\\\"s22\\\"></a><a name=\\\"section-6\\\"></a><p></p><h1>6 ADVERSE REACTIONS</h1><p class=\\\"First\\\">The following adverse reactions are discussed in greater detail in other sections of the labeling:</p><ul class=\\\"Disc\\\"><li>Diarrhea <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s16\\\">5.1</a>)]</span>.</li><li>Neutropenia <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s17\\\">5.2</a>)]</span>.</li><li>Interstitial Lung Disease (ILD) or Pneumonitis <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s18\\\">5.3</a>)]</span>.</li><li>Hepatotoxicity <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s19\\\">5.4</a>)]</span>.</li><li>Venous Thromboembolism <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s20\\\">5.5</a>)]</span>.</li></ul><div class=\\\"Section\\\" data-sectioncode=\\\"90374-0\\\"><a name=\\\"s23\\\"></a><a name=\\\"section-6.1\\\"></a><p></p><h2>6.1 Clinical Studies Experience</h2><p class=\\\"First\\\">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>The safety population described in the Warnings and Precautions reflect exposure to VERZENIO in 3691 patients from four clinical trials: monarchE, MONARCH 1, MONARCH 2, and MONARCH 3. The safety population includes exposure to VERZENIO as a single agent at 200 mg twice daily in 132 patients in MONARCH 1 and to VERZENIO at 150 mg twice daily in 3559 patients administered in combination with fulvestrant, tamoxifen, or an aromatase inhibitor in monarchE, MONARCH 2, and MONARCH 3. The median duration of exposure ranged from 4.5 months in MONARCH 1 to 24 months in monarchE. The most common adverse reactions (incidence ≥20%) across clinical trials were: diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, and thrombocytopenia.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s24\\\"></a><a name=\\\"section-6.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Bold\\\">Early Breast Cancer</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s25\\\"></a><a name=\\\"section-6.1.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">monarchE: VERZENIO in Combination with Tamoxifen or an Aromatase Inhibitor as Adjuvant Treatment</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s26\\\"></a><a name=\\\"section-6.1.1.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Adult patients with HR-positive, HER2-negative, node-positive early breast cancer at a high risk of recurrence</span></p><p>The safety of VERZENIO was evaluated in monarchE, a study of 5591 adult patients receiving VERZENIO plus endocrine therapy (tamoxifen or an aromatase inhibitor) or endocrine therapy (tamoxifen or an aromatase inhibitor) alone <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s98\\\">14.1</a>)].</span> Patients were randomly assigned to receive 150 mg of VERZENIO orally, twice daily, plus tamoxifen or an aromatase inhibitor, or tamoxifen or an aromatase inhibitor, for two years or until discontinuation criteria were met. The median duration of VERZENIO treatment was 24 months.</p><p>The most frequently reported (≥5%) Grade 3 or 4 adverse reactions were neutropenia, leukopenia, diarrhea, and lymphopenia.</p><p>Fatal adverse reactions occurred in 0.8% of patients who received VERZENIO plus endocrine therapy (tamoxifen or an aromatase inhibitor), including: cardiac failure (0.1%), cardiac arrest, myocardial infarction, ventricular fibrillation, cerebral hemorrhage, cerebrovascular accident, pneumonitis, hypoxia, diarrhea, and mesenteric artery thrombosis (0.03% each).</p><p>Permanent VERZENIO treatment discontinuation due to an adverse reaction was reported in 19% of patients receiving VERZENIO, plus tamoxifen or an aromatase inhibitor. Of the patients receiving tamoxifen or an aromatase inhibitor, 1% permanently discontinued due to an adverse reaction. The most common adverse reactions leading to VERZENIO discontinuations were diarrhea (5%), fatigue (2%), and neutropenia (0.9%).</p><p>Dose interruption of VERZENIO due to an adverse reaction occurred in 62% of patients receiving VERZENIO plus tamoxifen or aromatase inhibitors. Adverse reactions leading to VERZENIO dose interruptions in ≥5% of patients were diarrhea (20%), neutropenia (16%), leukopenia (7%), and fatigue (5%).</p><p>Dose reductions of VERZENIO due to an adverse reaction occurred in 44% of patients receiving VERZENIO plus endocrine therapy (tamoxifen or an aromatase inhibitor). Adverse reactions leading to VERZENIO dose reductions in ≥5% were diarrhea (17%), neutropenia (8%), and fatigue (5%).</p><p>The most common adverse reactions reported (≥20%) in the VERZENIO, plus tamoxifen or an aromatase inhibitor, arm and ≥2% higher than the tamoxifen or an aromatase inhibitor arm were: diarrhea, infections, neutropenia, fatigue, leukopenia, nausea, anemia, and headache. Adverse reactions are shown in <a href=\\\"#t8\\\">Table 8</a> and laboratory abnormalities are shown in <a href=\\\"#t9\\\">Table 9</a>.</p><a name=\\\"t8\\\"></a><table width=\\\"100%\\\"><caption><span>Table 8: Adverse Reactions (≥10%) of Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE</span></caption><col align=\\\"left\\\" width=\\\"34.957%\\\"/><col align=\\\"left\\\" width=\\\"13.329%\\\"/><col align=\\\"left\\\" width=\\\"10.000%\\\"/><col align=\\\"left\\\" width=\\\"9.171%\\\"/><col align=\\\"left\\\" width=\\\"12.729%\\\"/><col align=\\\"left\\\" width=\\\"9.829%\\\"/><col align=\\\"left\\\" width=\\\"9.986%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Includes the following fatal adverse reactions: diarrhea (n=1), and infections (n=4)</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Includes the following fatal adverse reactions: infections (n=5)</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Includes mouth ulceration, mucosal inflammation, oropharyngeal pain, stomatitis.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Includes all reported preferred terms that are part of the Infections and Infestations system organ class. Most common infections (&gt;5%) include upper respiratory tract infection, urinary tract infection, and nasopharyngitis.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">e</span> Includes asthenia, fatigue.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">f</span> Includes exfoliative rash, mucocutaneous rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculo-papular, rash maculovesicular, rash morbilliform, rash papular, rash papulosquamous, rash pruritic, rash vesicular, vulvovaginal rash.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO Plus</span><br/><span class=\\\"Bold\\\">Tamoxifen or an Aromatase Inhibitor</span><br/><span class=\\\"Bold\\\">N=2791</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Tamoxifen or an Aromatase Inhibitor</span><br/><span class=\\\"Bold\\\">N=2800</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">All Grades</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Grade 3</span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Grade 4</span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">All Grades</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Grade 3</span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Grade 4</span><br/><span class=\\\"Bold\\\">%</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Gastrointestinal Disorders</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Diarrhea</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">84</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Nausea</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">30</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">&lt;0.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\"